CLINICAL STUDY
A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis
Kwan-Leung Chan, MD, FRCPC, FACC*,*,
Jean G. Dumesnil, MD, FRCPC ,
Bibiana Cujec, MD, FRCPC ,
Anthony J. Sanfilippo, MD, FRCPC ,
John Jue, MD, FRCPC||,
Michele A. Turek, MD, FRCPC*,
Trevor I. Robinson, MD¶,
David Moher, MSc* Investigators of the Multicenter Aspirin Study in Infective Endocarditis
* Department of Medicine, University of Ottawa and University of Ottawa Heart Institute, Ottawa, Canada
Institut de Cardiologie de Québec, Ste-Foy, Quebec, Canada
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Department of Medicine, Queen's University, Kingston, Ontario, Canada
|| Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
¶ Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Manuscript received December 4, 2002;
revised manuscript received March 4, 2003,
accepted March 12, 2003.
* Reprint requests and correspondence: Dr. Kwan-Leung Chan, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada K1Y 4W7.
kchan{at}ottawaheart.ca
OBJECTIVES: This study examined the effect of aspirin on the risk of embolic events in infective endocarditis (IE).
BACKGROUND: Embolism is a major complication of IE, and studies in animal models have shown that platelet inhibition with aspirin can lead to more rapid vegetation resolution and a lower rate of embolic events.
METHODS: We conducted a randomized, double-blinded, placebo-controlled trial of aspirin treatment (325 mg/day) for four weeks in patients with IE to test the hypothesis that the addition of aspirin would reduce the incidence of clinical systemic embolic events. Patients with perivalvular abscess were excluded. Serial cerebral computed tomograms and transesophageal echocardiograms were obtained in a subset of patients.
RESULTS: During the four-year study period, 115 patients were enrolled: 60 assigned to aspirin and 55 assigned to placebo. Embolic events occurred in 17 patients (28.3%) on aspirin and 11 patients (20.0%) on placebo, with an odds ratio (OR) of 1.62 (95% confidence interval [CI] 0.68 to 3.86, p = 0.29). There was a trend toward a higher incidence of bleeding in the patients taking aspirin versus placebo (OR 1.92, 95% CI 0.76 to 4.86, p = 0.075). Development of new intracranial lesions was similar in both groups. Aspirin had no effect on vegetation resolution and valvular dysfunction.
CONCLUSIONS: In endocarditis patients already receiving antibiotic treatment, the addition of aspirin does not appear to reduce the risk of embolic events and is likely associated with an increased risk of bleeding. Aspirin is not indicated in the early management of patients with IE.
|
Abbreviations and Acronyms
| | CI | | confidence interval | | IE | | infective endocarditis | | OR | | odds ratio |
|
This article has been cited by other articles:
|
|
|
|
 
Endorsed by the European Society of Clinical Micro, Authors/Task Force Members, G. Habib, B. Hoen, P. Tornos, F. Thuny, B. Prendergast, I. Vilacosta, P. Moreillon, M. de Jesus Antunes, et al.
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC)
Eur. Heart J.,
October 1, 2009;
30(19):
2369 - 2413.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Daniel and F. A. Flachskampf
CHAPTER 22 Infective Endocarditis
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
December 2, 2008;
52(23):
e143 - e263.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation,
December 2, 2008;
118(23):
e714 - e833.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Durante-Mangoni, S. Bradley, C. Selton-Suty, M.-F. Tripodi, B. Barsic, E. Bouza, C. H. Cabell, A. I. d. O. Ramos, V. Fowler Jr, B. Hoen, et al.
Current Features of Infective Endocarditis in Elderly Patients: Results of the International Collaboration on Endocarditis Prospective Cohort Study
Arch Intern Med,
October 27, 2008;
168(19):
2095 - 2103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker
Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
593S - 629S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Sy, C. Chawantanpipat, D. R. Richmond, and L. Kritharides
Thrombocytopenia and Mortality in Infective Endocarditis
J. Am. Coll. Cardiol.,
May 6, 2008;
51(18):
1824 - 1825.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Baddour, W. R. Wilson, A. S. Bayer, V. G. Fowler Jr, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, et al.
Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America
Circulation,
June 14, 2005;
111(23):
e394 - e434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Peters
Infective Endocarditis
Journal of Diagnostic Medical Sonography,
May 1, 2005;
21(3):
192 - 204.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. H. Rahimtoola
The year in valvular heart disease
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
111 - 122.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Connolly, A. Choudhury, R. C. Davis, and G. Y. H. Lip
A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis
J. Am. Coll. Cardiol.,
March 17, 2004;
43(6):
1134 - 1135.
[Full Text]
[PDF]
|
|
|
|
